F-star Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Net loss
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization
Loss on disposal of property and equipment
Operating lease right-of-use asset amortization
Change in fair value of warrant liabilities
Share based compensation expense
Foreign currency (gain) loss
(Gain) loss on disposal of tangible fixed assets
Depreciation
Amortization
Interest expense
Non-cash investment income
Non-cash issuance of warrants to a service provider
Fair value adjustment of convertible term loan
Amortization of debt issuance costs
Fair Value Adjustments
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other assets
Tax incentive receivable
Research and development incentives receivable
Right of use asset
Other long-term assets
Accounts payable
Accounts payable to related parties
Accrued expenses and other current liabilities
Accrued interest payable
Operating lease liabilities
Deferred revenue
Lease obligations
Deferred tax liability
Payment to contingent value rights holders

Net cash used in operating activities
Cash flows from investing activities:
Purchase of property, plant and equipment
Net cash used in investing activities
Proceeds from Sale of Property, Plant, and Equipment
Cash acquired with transaction
Cash acquired with subsidiaries*
Proceeds from sale of marketable securities
Purchases of marketable securities
Purchase of intangible assets
Net cash (used in) provided by investing activities

Cash flows from financing activities:
Proceeds from term loan and warrants
Issuance costs in connection with term loan and warrants
Proceeds from Issuance of Common Stock
Proceeds from issuance of common stock in connection with at-the-market offering, net of issuance costs
Proceeds from exercise of warrants
Proceeds from exercise of stock options
Cash provided by financing activities
Proceeds received from long-term debt
Payment of debt issuance costs
Proceeds from issuance of convertible notes
Proceeds from private placement
Net cash provided by financing activities

Net increase in cash and cash equivalents
Cash, cash equivalents and restricted cash, end of period
Effect of exchange rate changes on cash
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental disclosures of cash flow information:
Cash paid for income taxes
Cash paid for amounts included in the measurement of operating lease
Cash paid for interest
Supplemental disclosure of non-cash information
Fair value of net assets acquired

Comments